A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer

Trial Title: A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer

NCT ID: NCT06144827

Condition: Cancer, Hepatocellular
Radiotherapy Side Effect

Conditions: Official terms:
Liver Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Non-Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Device
Intervention name: Multiparametric MRI scans
Description: Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
Arm group label: Multiparametric MRI scan group
Arm group label: Multiparametric MRI scans + HepQuantShunt Test group

Intervention type: Device
Intervention name: Multiparametric MRI scans + HepQuantShunt Test
Description: Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
Arm group label: Multiparametric MRI scans + HepQuantShunt Test group

Summary: The purpose of this study is to evaluate the role of quantitative MR imaging and blood-based biomarkers to measure liver function in patients receiving radiation therapy for liver cancer or cancer that has spread to the liver.

Detailed description: The purpose of this study is to evaluate the role of quantitative MR imaging and blood-based biomarkers to measure liver function in patients receiving radiation therapy for liver cancer or cancer that has spread to the liver. The feasibility of using MR imaging to monitor liver function at baseline and following liver radiation therapy will be determined. Information from MR images and blood samples, along with patient questionnaires, will be used.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Patient has the psychological ability and general health needed to provide informed consent, completion of study requirements, and required follow-up - Patient provides study-specific informed consent prior to study entry - All primary histologies (Hepatocellular carcinoma or Cholangiocarcinoma) as well as hepatic metastases are eligible - Prior history of radiation therapy (external beam or radioembolization) is allowed, with no limit to the number of prior courses of radiation therapy - Any number of lesions (with no size limit) of pathologically documented (histologically or cytologically) or radiographically proven tumor/metastasis that are being targeted - Prior history of chemotherapy, immunotherapy, or targeted biological therapy is allowed - Concurrent enrollment on other prospective registry or treatment intention trials is allowed Exclusion Criteria: - Pregnant or breast-feeding females - Subjects with history of claustrophobia impacting ability to perform MRI during the study - Subjects who fulfill any of the contraindications for MRI; examples include any ferromagnetic material, any metallic shrapnel or fragments or implanted electronic devices contained within the body or metal-containing tattoos - Unable to participate in MR assessments due to physical limitations of equipment tolerances (MRI bore size and/or weight limit) - Any person unable to lie still within the environment of the MRI scanner or maintain a breath hold for the required period to acquire images Exclusion criteria for HepQuant SHUNT testing ONLY: - Known history or suspected hypersensitivity to human serum albumin, or its preparations - Subjects with extensive resection of large segments of small intestine (short gut) or severe gastroparesis - Subjects on either a non-selective beta blocker (propranolol, nadolol) or an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) who are unwilling or unable to delay taking their normal dose the morning of their testing - Subjects who are allergic to any ingredient in the formulations or components in the HepQuant SHUNT kit including human serum albumin (HSA) or cholate compounds (theoretical - none yet reported) - Subjects unwilling or unable to fast for at least 5 hours. Fasting means no intake of food or food supplements, including fiber preparations or biosimilars; or, any preparations or resins (cholestyramine, colestipol, colesalvalem) that might act within the gut lumen to bind the orally administered d4-cholate in the HepQuant test

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Start date: October 2024

Completion date: October 2027

Lead sponsor:
Agency: Montefiore Medical Center
Agency class: Other

Collaborator:
Agency: HepQuant, LLC
Agency class: Industry

Collaborator:
Agency: Perspectum
Agency class: Industry

Source: Montefiore Medical Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06144827